<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03612544</url>
  </required_header>
  <id_info>
    <org_study_id>2017-02332e</org_study_id>
    <nct_id>NCT03612544</nct_id>
  </id_info>
  <brief_title>The ESTxENDS Trial- Toxins From Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)</brief_title>
  <acronym>ESTxENDS</acronym>
  <official_title>Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>State Hospital, St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Krebsforschung Schweiz, Bern, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federal Office of Public Health, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Bern</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cigarette smoking is the leading cause of preventable death in Switzerland. Recently,
      electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette)
      have become popular with smokers who want to stop smoking or reduce their exposure to inhaled
      chemicals since ENDS use appears to be safer than tobacco smoking.

      Conventional cigarettes release toxic chemicals in tobacco smoke through thermochemical
      degradation and pyrolysis processes by combusting tobacco, but in ENDS toxicants can be
      released by heating up nicotine-containing e-liquids to produce vapor. The e-liquid in ENDS
      is mostly made of propylene glycol (PG) and vegetal glycerin (VG) in addition to nicotine,
      flavorings and sometimes alcohol as a conservation agent. The heating process of the e-liquid
      in ENDS, has been shown to release carcinogens such as some carbonyl and volatile organic
      compounds (i.e., formaldehyde, acetaldehyde and acrolein). Some devices might also release
      heavy metals such as cadmium, lead and mercury. The source of such metals may be the metal of
      the device or the e-liquids. Although unexpected from the composition of the e-liquids, some
      studies have also detected tobacco-specific nitrosamines (TNSAs) (N'-nitrosonornicotine (NNN)
      and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)) and polycyclic aromatic
      hydrocarbons (PAHs) (1- and 2-Naphtol and 1-hydroxypyrene (1-OHP)).

      This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the
      safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and
      exposure to inhaled chemicals.

      For this trial, cigarette smokers motivated to quit smoking cigarettes will be included.
      Participants in the intervention group will receive an ENDS and nicotine-containing
      e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive
      smoking cessation counseling. Participants in the control group will receive smoking
      cessation counseling only. All participants will be followed over a 24-month period.
      Chemicals such as VOCs, PAHs, TSNAs, heavy metals, nicotine and nicotine degradation products
      will first be quantified in the aerosol produced by ENDS in laboratory conditions. These
      chemicals and their metabolites will then be measured at baseline and at 6-, 12- and 24-
      months' follow-up in urine samples from study participants.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Statisticians and laboratory personnel will be blinded to group allocation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNN (N-nitrosonornicotine)_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of NNN (N-nitrosonornicotine) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNN (N-nitrosonornicotine)_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of NNN (N-nitrosonornicotine) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNN (N-nitrosonornicotine)_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of NNN (N-nitrosonornicotine) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of NNK (nicotine-derived nitrosamine ketone) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of NNK (nicotine-derived nitrosamine ketone) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of NNK (nicotine-derived nitrosamine ketone) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary metabolites of VOCs (volatile organic compounds)_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurements of metabolites of VOCs in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary metabolites of VOCs (volatile organic compounds)_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurements of metabolites of VOCs in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary metabolites of VOCs (volatile organic compounds)_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurements of metabolites of VOCs in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary heavy metals_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of heavy metals in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary heavy metals_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of heavy metals in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary heavy metals_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of heavy metals in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary nicotine metabolites_1</measure>
    <time_frame>6 months post quit date</time_frame>
    <description>Measurement of nicotine metabolites in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary nicotine metabolites_2</measure>
    <time_frame>12 months post quit date</time_frame>
    <description>Measurement of nicotine metabolites in urine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of urinary nicotine metabolites_3</measure>
    <time_frame>24 months post quit date</time_frame>
    <description>Measurement of nicotine metabolites in urine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary NNN (N-nitrosonornicotine)</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of NNN (N-nitrosonornicotine) concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary NNK (nicotine-derived nitrosamine ketone)</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of NNK (nicotine-derived nitrosamine ketone) concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary VOCs (volatile organic compounds)</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of VOCs (volatile organic compounds) concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of PAHs (Polycyclic aromatic hydrocarbons) concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary heavy metals</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of heavy metals concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentrations of urinary nicotine metabolites</measure>
    <time_frame>Change from baseline to 6,12, 24 months post quit date</time_frame>
    <description>Change of nicotine metabolites concentrations in urine from baseline to 6, 12, and 24 months post quit date.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1172</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Toxicity</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ENDS (Vaporizer/e-cig) and smoking cessation counseling</intervention_name>
    <description>Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smoking cessation counseling</intervention_name>
    <description>Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Informed Consent as documented by signature

          -  Persons aged 18 or older

          -  Currently smoking 5 or more cigarettes a day for at least 12 months

          -  Willing to try to quit smoking within the next 3 months,

          -  Persons providing a valid phone number, a valid email address and/or a valid postal
             address.

        Exclusion criteria:

          -  Known hypersensitivity or allergy to contents of the e-liquid

          -  Participation in another study with investigational drug within the 30 days preceding
             the baseline visit and during the present study where interactions are to be expected

          -  Women who are pregnant or breast feeding

          -  Intention to become pregnant during the course of the scheduled study intervention,
             i.e. within the first 6-months of the study

          -  Persons having used ENDS or tobacco heating systems regularly in the 3 months
             preceding the baseline visit

          -  Persons having used nicotine replacement therapy (NRT) or other medications with
             demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion
             within the 3 months preceding the baseline visit

          -  Persons who cannot attend the 6- month follow-up visit for any reason

          -  Cannot understand instructions delivered in person or by phone, or otherwise unable to
             participate in study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reto Auer, Prof.Dr.med</last_name>
    <role>Study Director</role>
    <affiliation>Berner Institut für Hausarztmedizin; Universität Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reto Auer, Prof.Dr.med</last_name>
    <phone>+41 31 631 58 79</phone>
    <email>reto.auer@biham.unibe.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Schöni, Dr.</last_name>
    <phone>+41 31 631 58 66</phone>
    <email>anna.schoeni@biham.unibe.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivan Berlin, Prof.Dr.med</last_name>
      <email>ivan.berlin@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinic for General Internal Medicine, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Rodondi, Prof.Dr.med</last_name>
      <email>Nicolas.Rodondi@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département de médecine interne, Hôpitaux universitaires de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Paul Humair, PD Dr.med.</last_name>
      <email>Jean-Paul.Humair@hcuge.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenzentrum, Klinik für Pneumologie und Schlafmedizin, Kantonsspital St. Gallen</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Brutsche, Prof.Dr.med.</last_name>
      <email>Martin.Brutsche@kssg.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anja Frei, Dr.</last_name>
      <email>anja.frei@uzh.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Farsalinos KE, Polosa R. Safety evaluation and risk assessment of electronic cigarettes as tobacco cigarette substitutes: a systematic review. Ther Adv Drug Saf. 2014 Apr;5(2):67-86. doi: 10.1177/2042098614524430. Review.</citation>
    <PMID>25083263</PMID>
  </reference>
  <reference>
    <citation>Orr MS. Electronic cigarettes in the USA: a summary of available toxicology data and suggestions for the future. Tob Control. 2014 May;23 Suppl 2:ii18-22. doi: 10.1136/tobaccocontrol-2013-051474.</citation>
    <PMID>24732158</PMID>
  </reference>
  <reference>
    <citation>Bertholon JF, Becquemin MH, Roy M, Roy F, Ledur D, Annesi Maesano I, Dautzenberg B. [Comparison of the aerosol produced by electronic cigarettes with conventional cigarettes and the shisha]. Rev Mal Respir. 2013 Nov;30(9):752-7. doi: 10.1016/j.rmr.2013.03.003. Epub 2013 Apr 17. French.</citation>
    <PMID>24267765</PMID>
  </reference>
  <reference>
    <citation>Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction. 2011 Nov;106(11):2017-28. doi: 10.1111/j.1360-0443.2011.03505.x. Epub 2011 Jul 27.</citation>
    <PMID>21592253</PMID>
  </reference>
  <reference>
    <citation>Etter JF, Zäther E, Svensson S. Analysis of refill liquids for electronic cigarettes. Addiction. 2013 Sep;108(9):1671-9. doi: 10.1111/add.12235. Epub 2013 May 23.</citation>
    <PMID>23701634</PMID>
  </reference>
  <reference>
    <citation>Flouris AD, Poulianiti KP, Chorti MS, Jamurtas AZ, Kouretas D, Owolabi EO, Tzatzarakis MN, Tsatsakis AM, Koutedakis Y. Acute effects of electronic and tobacco cigarette smoking on complete blood count. Food Chem Toxicol. 2012 Oct;50(10):3600-3. doi: 10.1016/j.fct.2012.07.025. Epub 2012 Jul 31.</citation>
    <PMID>22858449</PMID>
  </reference>
  <reference>
    <citation>Goniewicz ML, Knysak J, Gawron M, Kosmider L, Sobczak A, Kurek J, Prokopowicz A, Jablonska-Czapla M, Rosik-Dulewska C, Havel C, Jacob P 3rd, Benowitz N. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014 Mar;23(2):133-9. doi: 10.1136/tobaccocontrol-2012-050859. Epub 2013 Mar 6.</citation>
    <PMID>23467656</PMID>
  </reference>
  <reference>
    <citation>Ingebrethsen BJ, Cole SK, Alderman SL. Electronic cigarette aerosol particle size distribution measurements. Inhal Toxicol. 2012 Dec;24(14):976-84. doi: 10.3109/08958378.2012.744781.</citation>
    <PMID>23216158</PMID>
  </reference>
  <reference>
    <citation>McAuley TR, Hopke PK, Zhao J, Babaian S. Comparison of the effects of e-cigarette vapor and cigarette smoke on indoor air quality. Inhal Toxicol. 2012 Oct;24(12):850-7. doi: 10.3109/08958378.2012.724728.</citation>
    <PMID>23033998</PMID>
  </reference>
  <reference>
    <citation>Pellegrino RM, Tinghino B, Mangiaracina G, Marani A, Vitali M, Protano C, Osborn JF, Cattaruzza MS. Electronic cigarettes: an evaluation of exposure to chemicals and fine particulate matter (PM). Ann Ig. 2012 Jul-Aug;24(4):279-88.</citation>
    <PMID>22913171</PMID>
  </reference>
  <reference>
    <citation>Uchiyama S, Ohta K, Inaba Y, Kunugita N. Determination of carbonyl compounds generated from the E-cigarette using coupled silica cartridges impregnated with hydroquinone and 2,4-dinitrophenylhydrazine, followed by high-performance liquid chromatography. Anal Sci. 2013;29(12):1219-22.</citation>
    <PMID>24334991</PMID>
  </reference>
  <reference>
    <citation>Walton KM, Abrams DB, Bailey WC, Clark D, Connolly GN, Djordjevic MV, Eissenberg TE, Fiore MC, Goniewicz ML, Haverkos L, Hecht SS, Henningfield JE, Hughes JR, Oncken CA, Postow L, Rose JE, Wanke KL, Yang L, Hatsukami DK. NIH electronic cigarette workshop: developing a research agenda. Nicotine Tob Res. 2015 Feb;17(2):259-69. doi: 10.1093/ntr/ntu214. Epub 2014 Oct 21.</citation>
    <PMID>25335949</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2018</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

